• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Viral Burden and Clearance in Asymptomatic COVID-19 Patients

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2022 Mar 16;9(5):ofac126.
doi: 10.1093/ofid/ofac126. eCollection 2022 May.
Viral Burden and Clearance in Asymptomatic COVID-19 Patients


Avanka B Gunatilaka[SUP] 1 2 [/SUP], Nicholas Marco[SUP] 3 [/SUP], Graham H Read[SUP] 1 [/SUP], Maggie Sweeney[SUP] 2 [/SUP], Greg Regan[SUP] 2 [/SUP], Cynthia Tsang[SUP] 1 [/SUP], Lobna Abdulrahman[SUP] 1 [/SUP], Swetha Ampabathina[SUP] 1 [/SUP], Archie Spindler[SUP] 2 [/SUP], Sarah S Lu[SUP] 2 [/SUP], Elena Schink[SUP] 1 [/SUP], Richard Gatti[SUP] 1 2 [/SUP], Christina Ingersoll[SUP] 2 [/SUP], Donatello Telesca[SUP] 3 [/SUP], Joanne B Weidhaas[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Containing coronavirus disease 2019 (COVID-19) has been difficult, due to both the large number of asymptomatic infected individuals and the long duration of infection. Managing these challenges requires understanding of the differences between asymptomatic vs symptomatic patients and those with a longer duration of infectivity.
Methods: Individuals from Los Angeles were tested for COVID-19, and a group positive for COVID-19 chose to have follow-up testing. Associations between symptoms and demographic factors, viral burden measured by cycle threshold (CT) value, and duration of polymerase chain reaction (PCR) positivity were analyzed.
Results: Eighteen point eight percent of patients were positive for COVID-19. Asymptomatic COVID-19-positive patients were significantly younger than symptomatic patients (2.6 years; P < .001). There were no differences in average CT between asymptomatic and symptomatic patients. The estimated median duration of COVID-19 PCR positivity was 23 days. Being asymptomatic throughout the course of infection was the only factor associated with a shorter course of COVID-19 PCR positivity (21 vs 28 days; P = .002).
Conclusions: We found important differences and similarities between asymptomatic and symptomatic COVID-19-positive patients, the most meaningful being a similar level of virus as measured by PCR, but a shorter duration of PCR positivity for asymptomatic patients. These findings suggest that asymptomatic patients may have more efficient clearance of virus, which may be relevant for management and screening.

Keywords: COVID-19; asymptomatic; duration; viral burden.
 
Back
Top Bottom